EMB
VRTX icon

Elefante Mark B’s Vertex Pharmaceuticals VRTX Stock Holding History

Elefante Mark B’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.61M Buy
9,285
+1,144
+14% +$507K 1.99% 22
2026
Q1 		$3.64M Buy
8,141
+1,126
+16% +$525K 2% 24
2025
Q4 		$3.18M Buy
7,015
+352
+5% +$152K 1.95% 22
2025
Q3 		$2.61M Buy
6,663
+831
+14% +$347K 1.67% 25
2025
Q2 		$2.6M Buy
5,832
+171
+3% +$78.8K 1.95% 25
2025
Q1 		$2.74M Buy
5,661
+1,109
+24% +$517K 2.17% 25
2024
Q4 		$1.83M Buy
+4,552
New +$2.11M 1.67% 26

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Elefante Mark B's VRTX Position: Q2 2026 in Review

Elefante Mark B increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q2 2026, buying an estimated $507K and bringing the position to 9,285 shares worth $4.61M. The position accounts for 1.99% of the portfolio, ranked #22.

Elefante Mark B first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Elefante Mark B held 9,285 shares of Vertex Pharmaceuticals worth $4.61M as of Q2 2026.
  • Elefante Mark B bought 1,144 Vertex Pharmaceuticals shares in Q2 2026, an estimated $507K.
  • Vertex Pharmaceuticals made up 1.99% of Elefante Mark B's portfolio in Q2 2026, its #22 holding.
  • Elefante Mark B first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Elefante Mark B's 13F filing for Q2 2026, filed 13 Aug 2026.